282 related articles for article (PubMed ID: 26810134)
1. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout.
Roberts RL; Wallace MC; Phipps-Green AJ; Topless R; Drake JM; Tan P; Dalbeth N; Merriman TR; Stamp LK
Pharmacogenomics J; 2017 Mar; 17(2):201-203. PubMed ID: 26810134
[TBL] [Abstract][Full Text] [Related]
2. Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis.
Wallace MC; Roberts RL; Nanavati P; Miner JN; Dalbeth N; Topless R; Merriman TR; Stamp LK
Rheumatology (Oxford); 2018 Apr; 57(4):656-660. PubMed ID: 29342288
[TBL] [Abstract][Full Text] [Related]
3. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
Torres RJ; Puig JG
Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response.
Wen CC; Yee SW; Liang X; Hoffmann TJ; Kvale MN; Banda Y; Jorgenson E; Schaefer C; Risch N; Giacomini KM
Clin Pharmacol Ther; 2015 May; 97(5):518-25. PubMed ID: 25676789
[TBL] [Abstract][Full Text] [Related]
5. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
[TBL] [Abstract][Full Text] [Related]
6. Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Merriman TR; Wright DFB; Drake J; Dalbeth N
Clin Transl Sci; 2020 Jan; 13(1):110-115. PubMed ID: 31444839
[TBL] [Abstract][Full Text] [Related]
7. Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Rheumatology (Oxford); 2012 Sep; 51(9):1670-6. PubMed ID: 22539486
[TBL] [Abstract][Full Text] [Related]
8. The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool.
Wright DFB; Dalbeth N; Phipps-Green AJ; Merriman TR; Barclay ML; Drake J; Tan P; Horne A; Stamp LK
Br J Clin Pharmacol; 2018 May; 84(5):937-943. PubMed ID: 29341237
[TBL] [Abstract][Full Text] [Related]
9. Clinical and genetic features of diuretic-associated gout: a case-control study.
Mitnala S; Phipps-Green A; Franklin C; Horne A; Stamp LK; Merriman TR; Dalbeth N
Rheumatology (Oxford); 2016 Jul; 55(7):1172-6. PubMed ID: 26989110
[TBL] [Abstract][Full Text] [Related]
10. An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites.
Pilon MO; Leclair G; Oussaïd E; St-Jean I; Jutras M; Gaulin MJ; Mongrain I; Busseuil D; Rouleau JL; Tardif JC; Dubé MP; de Denus S
Clin Transl Sci; 2022 Aug; 15(8):2024-2034. PubMed ID: 35689378
[TBL] [Abstract][Full Text] [Related]
11. ABCG2 gene polymorphism rs2231142 is associated with gout comorbidities but not allopurinol response in primary gout patients of a Chinese Han male population.
Zhang K; Li C
Hereditas; 2019; 156():26. PubMed ID: 31367212
[TBL] [Abstract][Full Text] [Related]
12. Plasma oxypurinol as a measure of adherence in clinical trials.
Stamp LK; Merriman T; Frampton C; Zhang M; Wallace M; Miner JN; Dalbeth N
Ann Rheum Dis; 2018 Feb; 77(2):313-314. PubMed ID: 28057666
[No Abstract] [Full Text] [Related]
13. Predicting allopurinol response in patients with gout.
Wright DF; Duffull SB; Merriman TR; Dalbeth N; Barclay ML; Stamp LK
Br J Clin Pharmacol; 2016 Feb; 81(2):277-89. PubMed ID: 26451524
[TBL] [Abstract][Full Text] [Related]
14. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
Keith MP; Gilliland WR
Clin Pharmacol Ther; 2011 Sep; 90(3):363-4. PubMed ID: 21862966
[TBL] [Abstract][Full Text] [Related]
15. The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients.
Stiburkova B; Pavelcova K; Pavlikova M; Ješina P; Pavelka K
Arthritis Res Ther; 2019 Mar; 21(1):77. PubMed ID: 30894219
[TBL] [Abstract][Full Text] [Related]
16. Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout.
Stamp LK; Merriman TR; Barclay ML; Singh JA; Roberts RL; Wright DF; Dalbeth N
Semin Arthritis Rheum; 2014 Oct; 44(2):170-4. PubMed ID: 24925693
[TBL] [Abstract][Full Text] [Related]
17. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
18. Individualising the dose of allopurinol in patients with gout.
Kannangara DRW; Graham GG; Wright DFB; Stocker SL; Portek I; Pile KD; Barclay ML; Williams KM; Stamp LK; Day RO
Br J Clin Pharmacol; 2017 Sep; 83(9):2015-2026. PubMed ID: 28417592
[TBL] [Abstract][Full Text] [Related]
19. A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout.
Phang KF; Santosa A; Low BPL; Tan PSH; Khong ZW; Lim AYN; Teng GG; Tay SH
Int J Rheum Dis; 2020 Aug; 23(9):1136-1144. PubMed ID: 32483906
[TBL] [Abstract][Full Text] [Related]
20. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]